Capricor Therapeutics (CAPR) Price & Analysis

Compare

1,084 Followers

CAPR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.71 - $23.40

Previous CloseN/A

Volume187.65K

Average Volume (3M)2.43M

Market Cap

$414.57M

Enterprise Value$292.94M

Total Cash (Recent Filing)$144.78M

Total Debt (Recent Filing)$1.25M

Price to Earnings (P/E)―

Beta2.32

Next Earnings

Nov 12, 2025

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding45,707,820

10 Day Avg. Volume1,956,838

30 Day Avg. Volume2,425,927

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.71

Enterprise Value/Revenue16.87

Enterprise Value/Gross Profit18.00

Enterprise Value/Ebitda-5.25

Forecast

1Y Price Target

$19.90

Price Target Upside154.48% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe company is well-capitalized with $120M in cash, providing a financial runway.

Regulatory EnvironmentFDA has signaled willingness to work with sponsors on areas of high unmet need, suggesting a more favorable approval pathway for rare diseases.

Bears Say

Clinical Trial EvidenceThe CRL cited a lack of substantial evidence of effectiveness and the need for more clinical data.

Regulatory ChallengesThe FDA will not hold an Adcom meeting for deramiocel in Duchenne Muscular Dystrophy, increasing regulatory risk.

Capricor Therapeutics News

Capricor Therapeutics reports Q2 EPS (57c), consensus (48c)

Cash, cash equivalents and marketable securities totaled approximately $122.8M as of June 30. The company says its cash...

15h ago

CAPR

Capricor Therapeutics options imply 14.8% move in share price post-earnings

Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with puts leading calls 19:5. Implied volatility suggests the...

17h ago

CAPR

Video: Nvidia, AMD said to pay U.S. 15% of revenue from China chip sales

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

23h ago

ALB

Vinay Prasad returns to FDA as head of CBER

Vinay Prasad is returning to the Food and Drug Administration to lead the Center for Biologics Evaluation and...

3d ago

CAPR

MGTX

Capricor Therapeutics announces Type A meeting scheduled with U.S. FDA

Capricor Therapeutics (CAPR) announced that a Type A meeting with the U.S. Food and Drug Administration, FDA, has...

4d ago

CAPR

Capricor Therapeutics call volume above normal and directionally bullish

Bullish option flow detected in Capricor Therapeutics (CAPR) with 2,400 calls trading, 1.4x expected, and implied vol increasing...

13d ago

CAPR

Biotech stocks rise following Prasad exit from FDA

Shares of several biotech names are on the rise on Wednesday after Vinay Prasad, a top regulator at...

13d ago

BHVN

CAPR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Sangamo (SGMO) 1.72% +0.48,...

18d ago

CAN

Capricor Therapeutics price target lowered to $12 from $31 at Roth Capital

Roth Capital lowered the firm’s price target on Capricor Therapeutics (CAPR) to $12 from $31 and keeps a...

29d ago

CAPR

Capricor Therapeutics price target lowered to $16 from $20 at Alliance Global

Alliance Global Partners lowered the firm’s price target on Capricor Therapeutics (CAPR) to $16 from $20 and keeps...

29d ago

CAPR

Capricor Therapeutics: Strong Financial Position and Strategic Initiatives Drive Buy Rating Despite Regulatory Challenges

H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CAPR stock, giving a Buy rating today....

1h ago

CAPR

Capricor Therapeutics: Q2 2025 Financial and Strategic Update

Capricor Therapeutics, Inc. ( ($CAPR) ) has released its Q2 earnings. Here is a breakdown of the information...

8h ago

CAPR

Capricor Therapeutics, Inc. (CAPR) Q2 Earnings Cheat Sheet

Capricor Therapeutics, Inc. (CAPR) is scheduled to report 2nd quarter earnings on 08/13/2025, after the market closes. Regarding...

1d ago

CAPR

Capricor Therapeutics: Strategic Refinement and Optimism for Deramiocel’s FDA Approval

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Capricor Therapeutics today and set a price target...

13d ago

CAPR

CAPR FAQ

What was Capricor Therapeutics’s price range in the past 12 months?

Capricor Therapeutics lowest stock price was $3.71 and its highest was $23.40 in the past 12 months.

What is Capricor Therapeutics’s market cap?

Capricor Therapeutics’s market cap is $414.57M.

When is Capricor Therapeutics’s upcoming earnings report date?

Capricor Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 92 days.

How were Capricor Therapeutics’s earnings last quarter?

Capricor Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.476 by -$0.094.

Is Capricor Therapeutics overvalued?

According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Capricor Therapeutics pay dividends?

Capricor Therapeutics does not currently pay dividends.

What is Capricor Therapeutics’s EPS estimate?

Capricor Therapeutics’s EPS estimate is -0.48.

How many shares outstanding does Capricor Therapeutics have?

Capricor Therapeutics has 45,707,820 shares outstanding.

What happened to Capricor Therapeutics’s price movement after its last earnings report?

Capricor Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.476. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Capricor Therapeutics?

Currently, no hedge funds are holding shares in CAPR

Capricor Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-120.15%

Trailing 12-Months

Asset Growth

210.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Capricor Therapeutics

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Capricor Therapeutics (CAPR) Earnings & Revenues

Historic Earnings Reports

CAPR Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted positive advancements in the approval process for deramiocel, strong safety and efficacy data, strategic partnerships, and a solid financial position. However, the decline in revenue, increased expenses, and significant net loss cast some concerns on the financial performance. Despite these financial challenges, the strategic and clinical advancements suggest a cautiously optimistic outlook.View all CAPR earnings summaries

CAPR Stock 12 Month Forecast

Average Price Target

$19.90

▲(154.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","23":"$23","30":"$30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9,16,23,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.9,9.523076923076923,11.146153846153847,12.76923076923077,14.392307692307693,16.015384615384615,17.63846153846154,19.261538461538464,20.884615384615387,22.50769230769231,24.130769230769232,25.753846153846155,27.376923076923077,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.9,8.823076923076924,9.746153846153845,10.669230769230769,11.592307692307692,12.515384615384615,13.438461538461539,14.36153846153846,15.284615384615384,16.207692307692305,17.130769230769232,18.053846153846152,18.976923076923075,{"y":19.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.9,7.907692307692308,7.915384615384616,7.923076923076923,7.930769230769231,7.938461538461539,7.946153846153846,7.953846153846154,7.961538461538462,7.969230769230769,7.976923076923077,7.984615384615385,7.992307692307692,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.84,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.91,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.57,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.01,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.38,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.48,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >